0001209191-24-000844.txt : 20240104
0001209191-24-000844.hdr.sgml : 20240104
20240104170511
ACCESSION NUMBER: 0001209191-24-000844
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Simpson Adam K.
CENTRAL INDEX KEY: 0001873839
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40655
FILM NUMBER: 24513087
MAIL ADDRESS:
STREET 1: C/O ICOSAVAX, INC.
STREET 2: 1616 EASTLAKE AVENUE E., SUITE 208
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Icosavax, Inc.
CENTRAL INDEX KEY: 0001786255
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1930 BOREN AVE., SUITE 1000
CITY: SEATTLE
STATE: WA
ZIP: 98101
BUSINESS PHONE: (206) 737-0085
MAIL ADDRESS:
STREET 1: 1930 BOREN AVE., SUITE 1000
CITY: SEATTLE
STATE: WA
ZIP: 98101
4
1
doc4.xml
FORM 4 SUBMISSION
X0508
4
2024-01-02
0
0001786255
Icosavax, Inc.
ICVX
0001873839
Simpson Adam K.
C/O ICOSAVAX, INC.
1930 BOREN AVE., SUITE 1000
SEATTLE
WA
98101
1
1
0
0
Chief Executive Officer
1
Common Stock
2024-01-02
4
M
0
15000
1.04
A
275641
D
Common Stock
2024-01-02
4
S
0
15000
15.6725
D
260641
D
Common Stock
531576
I
By family trust
Common Stock
129032
I
By family trust
Common Stock
129032
I
By family trust
Stock Option (Right to Buy)
1.04
2024-01-02
4
M
0
15000
0.00
D
2031-01-28
Common Stock
15000
299676
D
The sales were effected pursuant to a Rule 10b5-1 instruction letter dated September 16, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $15.76. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on January 14, 2022, and 1/48th of the shares subject to the option vest monthly thereafter.
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
2024-01-04